185 related articles for article (PubMed ID: 37738533)
1. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
[TBL] [Abstract][Full Text] [Related]
2. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
3. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
5. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
6. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
8. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Gibofsky A; McCabe D
Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
[TBL] [Abstract][Full Text] [Related]
9. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: Implications for health-system pharmacists.
Lucio SD; Stevenson JG; Hoffman JM
Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
[TBL] [Abstract][Full Text] [Related]
11. Implementing and Optimizing Biosimilar Use at Mayo Clinic.
Jensen CJ; Tichy EM; Lempke MB; Ewald AM; Erickson SJ; Holm MR; Soefje SA
Mayo Clin Proc; 2022 Jun; 97(6):1086-1093. PubMed ID: 35337661
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
13. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A; Furtner D; Melsheimer R; Molloy PJ
Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
[TBL] [Abstract][Full Text] [Related]
14. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
Hair J; Maryon T; Lieneck C
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
[TBL] [Abstract][Full Text] [Related]
15. FDA Expectations for Demonstrating Interchangeability.
Chance K
Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
[TBL] [Abstract][Full Text] [Related]
16. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
17. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
[TBL] [Abstract][Full Text] [Related]
18. Understanding State Regulation of Biosimilars and Effect on Prescribers.
Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
[TBL] [Abstract][Full Text] [Related]
19. Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement.
Ho RJ
J Pharm Sci; 2017 Feb; 106(2):471-476. PubMed ID: 27876365
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
